Michelle Janisch: Breast Cancer Index team presented data at ASCO24

Michelle Janisch, VP Marketing and Strategic Alliances at Hologic Inc., made the following post on LinkedIn:

“Last weekend, our Breast Cancer Index team presented data at ASCO24 that suggests a significant group of Breast Cancer patients and their providers may make inappropriate extended endocrine therapy (EET) treatment decisions if they only base the decision on test results that are intended to inform chemotherapy benefit.

One size doesn’t fit all when developing treatment plans, as deciding whether to extend endocrine therapy – and balancing potential EET side effects with risk of recurrence – is an incredibly personal decision.

And as the only genomic test recognized by major guidelines to predict which patients are likely to benefit from EET, we’re proud that the Breast Cancer Index test is trusted to help make that choice.

Read more on the data here.”

Source: Michelle Janisch/LinkedIn